Published in J Exp Med on June 01, 1988
The complex pattern of cytokines in serum from patients with meningococcal septic shock. Association between interleukin 6, interleukin 1, and fatal outcome. J Exp Med (1989) 6.99
Antibodies to cachectin/tumor necrosis factor reduce interleukin 1 beta and interleukin 6 appearance during lethal bacteremia. J Exp Med (1989) 4.66
T cell-mediated lethal shock triggered in mice by the superantigen staphylococcal enterotoxin B: critical role of tumor necrosis factor. J Exp Med (1992) 4.31
Local production of tumor necrosis factor alpha, interleukin 1, and interleukin 6 in meningococcal meningitis. Relation to the inflammatory response. J Exp Med (1989) 2.68
Tumor necrosis factor alpha and interleukin 1beta are responsible for in vitro myocardial cell depression induced by human septic shock serum. J Exp Med (1996) 2.50
The intratracheal administration of endotoxin and cytokines. I. Characterization of LPS-induced IL-1 and TNF mRNA expression and the LPS-, IL-1-, and TNF-induced inflammatory infiltrate. Am J Pathol (1991) 2.30
Interferon gamma, a mediator of lethal lipopolysaccharide-induced Shwartzman-like shock reactions in mice. J Exp Med (1990) 2.25
Functions of interleukin 1 receptor antagonist in gene knockout and overproducing mice. Proc Natl Acad Sci U S A (1996) 2.18
A recombinant human receptor antagonist to interleukin 1 improves survival after lethal endotoxemia in mice. J Exp Med (1991) 2.14
IL-18 and IL-12 induce intestinal inflammation and fatty liver in mice in an IFN-gamma dependent manner. Gut (2000) 1.95
Role of tumor necrosis factor-alpha in lipopolysaccharide-induced pathologic alterations. Am J Pathol (1990) 1.66
Circulating interleukin 6 during a continuous infusion of tumor necrosis factor and interferon gamma. J Exp Med (1989) 1.59
Interleukin-1 receptor blockade improves survival and hemodynamic performance in Escherichia coli septic shock, but fails to alter host responses to sublethal endotoxemia. J Clin Invest (1992) 1.58
Neutral endopeptidase modulation of septic shock. J Exp Med (1995) 1.53
The complex pattern of cytokines in sepsis. Association between prostaglandins, cachectin, and interleukins. Ann Surg (1991) 1.48
Resistance to lipopolysaccharide mediated by the Yersinia pestis V antigen-polyhistidine fusion peptide: amplification of interleukin-10. Infect Immun (1997) 1.45
Decreased mortality of severe acute pancreatitis after proximal cytokine blockade. Ann Surg (1995) 1.41
The role of inflammatory mediators in the pathogenesis of otitis media and sequelae. Clin Exp Otorhinolaryngol (2008) 1.36
Protection from endotoxic shock in mice by pharmacologic inhibition of phosphatidic acid. Proc Natl Acad Sci U S A (1994) 1.31
Wild-type Puumala hantavirus infection induces cytokines, C-reactive protein, creatinine, and nitric oxide in cynomolgus macaques. J Virol (2002) 1.27
Lactoferrin regulates the release of tumour necrosis factor alpha and interleukin 6 in vivo. Int J Exp Pathol (1993) 1.26
Protection against endotoxic shock and lipopolysaccharide-induced local inflammation by tetracycline: correlation with inhibition of cytokine secretion. Infect Immun (1996) 1.24
Functional characterization of the human tumor necrosis factor receptor p75 in a transfected rat/mouse T cell hybridoma. J Exp Med (1992) 1.17
Requirements for tumor necrosis factor-alpha and interleukin-1 in limb ischemia/reperfusion injury and associated lung injury. Am J Pathol (1993) 1.17
Differentiation factor/leukemia inhibitory factor protection against lethal endotoxemia in mice: synergistic effect with interleukin 1 and tumor necrosis factor. J Exp Med (1992) 1.12
Human rTNF alpha augments anti-bacterial resistance in mice: potentiation of its effects by recombinant human rIL-1 alpha. Immunology (1990) 1.06
Experimental elimination of tumor necrosis factor in low-dose endotoxin models has variable effects on survival. Infect Immun (1991) 1.06
Intraperitoneal injection of tetracyclines protects mice from lethal endotoxemia downregulating inducible nitric oxide synthase in various organs and cytokine and nitrate secretion in blood. Antimicrob Agents Chemother (1997) 1.01
Tumor necrosis factor alpha and interleukin 1beta enhance the cortisone/cortisol shuttle. J Exp Med (1997) 0.94
Binding of lysozyme to lipopolysaccharide suppresses tumor necrosis factor production in vivo. Infect Immun (1994) 0.93
Dehydroepiandrosterone protects mice from endotoxin toxicity and reduces tumor necrosis factor production. Antimicrob Agents Chemother (1992) 0.92
A role for interleukin-1 alpha in immunologically mediated intestinal pathology. Immunology (1993) 0.91
Study of the effector mechanism involved in the production of haemorrhagic necrosis of the small intestine in rat passive anaphylaxis. Br J Pharmacol (1994) 0.89
Relationships between tumour necrosis factor, eicosanoids and platelet-activating factor as mediators of endotoxin-induced shock in mice. Br J Pharmacol (1990) 0.89
Absence of tumor necrosis factor-alpha in suction blister fluids and stratum corneum from patients with psoriasis. Arch Dermatol Res (1989) 0.88
Science review: key inflammatory and stress pathways in critical illness - the central role of the Toll-like receptors. Crit Care (2002) 0.88
Inhibition of macrophage-activating cytokines is beneficial in the acute septic response. Ann Surg (1991) 0.87
Neutralization of microcystin shock in mice by tumor necrosis factor alpha antiserum. Appl Environ Microbiol (1991) 0.85
Early induction of IL-1 receptor antagonist (IL-1Ra) in infants and children undergoing surgery. Clin Exp Immunol (1993) 0.81
Increasing the efficacy of anti-inflammatory agents used in the treatment of sepsis. Eur J Clin Microbiol Infect Dis (2003) 0.81
Cerebrospinal fluid levels of interleukin-6 and interleukin-12 in children with meningitis. Childs Nerv Syst (2008) 0.81
Altered in vivo activity of liposome-incorporated lipopolysaccharide and lipid A. Infect Immun (1989) 0.77
Inhibition of human monocyte adhesion to endothelial cells by the coumarin derivative, cloricromene. Br J Pharmacol (1994) 0.76
Unopposed interleukin-1 is necessary for increased plasma cytokine and eicosanoid levels to develop in severe sepsis. Ann Surg (1997) 0.75
Zymosan-Induced Peritonitis: Effects on Cardiac Function, Temperature Regulation, Translocation of Bacteria, and Role of Dectin-1. Shock (2016) 0.75
Passive immunization against cachectin/tumor necrosis factor protects mice from lethal effect of endotoxin. Science (1985) 19.41
Shock and tissue injury induced by recombinant human cachectin. Science (1986) 16.24
Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia. Nature (1988) 13.42
Tumor necrosis factor (cachectin) is an endogenous pyrogen and induces production of interleukin 1. J Exp Med (1986) 10.91
Cachectin: more than a tumor necrosis factor. N Engl J Med (1987) 8.74
Tumor necrosis factor and interleukin 1: cytokines with multiple overlapping biological activities. Lab Invest (1987) 7.95
Association between tumour necrosis factor in serum and fatal outcome in patients with meningococcal disease. Lancet (1987) 7.24
Recombinant tumor necrosis factor induces procoagulant activity in cultured human vascular endothelium: characterization and comparison with the actions of interleukin 1. Proc Natl Acad Sci U S A (1986) 5.83
An endothelial cell surface factor(s) induced in vitro by lipopolysaccharide, interleukin 1, and tumor necrosis factor-alpha increases neutrophil adherence by a CDw18-dependent mechanism. J Immunol (1986) 5.14
Cloning and expression in Escherichia coli of the cDNA for murine tumor necrosis factor. Proc Natl Acad Sci U S A (1985) 4.42
The role of cachectin/TNF in endotoxic shock and cachexia. Immunol Today (1988) 3.40
Synergy between tumor necrosis factor and bacterial products causes hemorrhagic necrosis and lethal shock in normal mice. Proc Natl Acad Sci U S A (1988) 3.04
Properties of a specific interleukin 1 (IL 1) receptor on human Epstein Barr virus-transformed B lymphocytes: identity of the receptor for IL 1-alpha and IL 1-beta. J Immunol (1986) 2.49
Criteria for analyzing interactions between biologically active agents. Adv Cancer Res (1981) 2.49
Recombinant interleukin 1 suppresses lipoprotein lipase activity in 3T3-L1 cells. J Immunol (1985) 2.21
The toxic effects of tumor necrosis factor in vivo and their prevention by cyclooxygenase inhibitors. Proc Natl Acad Sci U S A (1987) 2.10
Purification and characterization of human interleukin-1 beta expressed in recombinant Escherichia coli. Eur J Biochem (1986) 1.89
Purification and characterization of human interleukin-1 alpha produced in Escherichia coli. Eur J Biochem (1987) 1.28
Synergistic anti-proliferative activity of interleukin 1 and tumor necrosis factor. J Immunol (1987) 1.20
A highly sensitive cell line, WEHI 164 clone 13, for measuring cytotoxic factor/tumor necrosis factor from human monocytes. J Immunol Methods (1986) 8.88
Association between tumour necrosis factor in serum and fatal outcome in patients with meningococcal disease. Lancet (1987) 7.24
The complex pattern of cytokines in serum from patients with meningococcal septic shock. Association between interleukin 6, interleukin 1, and fatal outcome. J Exp Med (1989) 6.99
Toll-like receptor 2 functions as a pattern recognition receptor for diverse bacterial products. J Biol Chem (1999) 5.81
Inhibition of cytokine production by cyclosporin A and transforming growth factor beta. J Exp Med (1987) 4.35
Soluble CD14 participates in the response of cells to lipopolysaccharide. J Exp Med (1992) 4.02
Inhibition of cytotoxic T cell development by transforming growth factor beta and reversal by recombinant tumor necrosis factor alpha. J Exp Med (1987) 3.03
Local production of tumor necrosis factor alpha, interleukin 1, and interleukin 6 in meningococcal meningitis. Relation to the inflammatory response. J Exp Med (1989) 2.68
Human toll-like receptor 2 mediates monocyte activation by Listeria monocytogenes, but not by group B streptococci or lipopolysaccharide. J Immunol (2000) 2.49
Serum levels of tumor necrosis factor-alpha (TNF alpha) and soluble TNF receptors in human immunodeficiency virus type 1 infection--correlations to clinical, immunologic, and virologic parameters. J Infect Dis (1994) 1.93
Effect of high- versus low-dose angiotensin converting enzyme inhibition on cytokine levels in chronic heart failure. J Am Coll Cardiol (1999) 1.86
Elevated levels of serum-soluble CD14 in human immunodeficiency virus type 1 (HIV-1) infection: correlation to disease progression and clinical events. Blood (1998) 1.83
Tumor necrosis factor alpha/cachectin is a growth factor for thymocytes. Synergistic interactions with other cytokines. J Exp Med (1988) 1.82
Endotoxin, tumor necrosis factor-alpha and interleukin 1 induce interleukin 6 production in vivo. Clin Immunol Immunopathol (1989) 1.76
Involvement of CD14 and toll-like receptors in activation of human monocytes by Aspergillus fumigatus hyphae. Infect Immun (2001) 1.75
A comparative study of IL-12 (cytotoxic lymphocyte maturation factor)-, IL-2-, and IL-7-induced effects on immunomagnetically purified CD56+ NK cells. J Immunol (1992) 1.75
Toll-like receptors mediate proliferation and survival of multiple myeloma cells. Leukemia (2006) 1.63
Decreased bone formative and enhanced resorptive markers in human immunodeficiency virus infection: indication of normalization of the bone-remodeling process during highly active antiretroviral therapy. J Clin Endocrinol Metab (1999) 1.61
Differential expression of Toll-like receptor 2 in human cells. J Leukoc Biol (2001) 1.58
Cytokine network in congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol (1999) 1.50
Cytokine regulation of interleukin 6 production by human endothelial cells. Cell Immunol (1989) 1.46
Binding and regulation of cellular functions by monoclonal antibodies against human tumor necrosis factor receptors. J Exp Med (1990) 1.39
Myocardial ischaemia and the inflammatory response: release of heat shock protein 70 after myocardial infarction. Heart (2005) 1.38
Innate immune responses to danger signals in systemic inflammatory response syndrome and sepsis. Scand J Immunol (2009) 1.37
Interleukin-6 in synovial fluid from patients with arthritis. Clin Immunol Immunopathol (1989) 1.35
Involvement of CD14 and complement receptors CR3 and CR4 in nuclear factor-kappaB activation and TNF production induced by lipopolysaccharide and group B streptococcal cell walls. J Immunol (1998) 1.34
Detection of tumour necrosis factor-like cytotoxicity in serum from patients with septicaemia but not from untreated cancer patients. Scand J Immunol (1986) 1.29
Poly-L-Lysine induces fibrosis on alginate microcapsules via the induction of cytokines. Cell Transplant (2001) 1.26
Interleukin 4 induces selective production of interleukin 6 from normal human B lymphocytes. J Exp Med (1989) 1.26
Induction of cytokine production from human monocytes stimulated with alginate. J Immunother (1991) (1991) 1.23
The involvement of human tumor necrosis factors-alpha and -beta in the mixed lymphocyte reaction. J Immunol (1988) 1.20
Successful reversal of spontaneous diabetes in dogs by intraperitoneal microencapsulated islets. Transplantation (1992) 1.16
Involvement of the 55- and 75-kDa tumor necrosis factor receptors in the generation of lymphokine-activated killer cell activity and proliferation of natural killer cells. J Immunol (1991) 1.16
Immunohistochemical localization of Toll-like receptors 2 and 4 in gingival tissue from patients with periodontitis. Oral Microbiol Immunol (2003) 1.15
Tumor necrosis factor receptor p75 mediates cell-specific activation of nuclear factor kappa B and induction of human cytomegalovirus enhancer. J Biol Chem (1994) 1.13
Release of cytokines, soluble cytokine receptors, and interleukin-1 receptor antagonist after intravenous immunoglobulin administration in vivo. Blood (1994) 1.12
A novel synthetic acyclic lipid A-like agonist activates cells via the lipopolysaccharide/toll-like receptor 4 signaling pathway. J Biol Chem (2000) 1.12
Alginate polycation microcapsules. II. Some functional properties. Biomaterials (1996) 1.11
Alginate polycation microcapsules. I. Interaction between alginate and polycation. Biomaterials (1996) 1.11
Alginate-polylysine-alginate microcapsules: effect of size reduction on capsule properties. J Microencapsul (2002) 1.07
Lipopolysaccharide induces expression of APO2 ligand/TRAIL in human monocytes and macrophages. Scand J Immunol (2000) 1.07
Long-term reversal of diabetes by the injection of immunoprotected islets. Proc Natl Acad Sci U S A (1993) 1.07
Similar mechanisms of action of defined polysaccharides and lipopolysaccharides: characterization of binding and tumor necrosis factor alpha induction. Infect Immun (1993) 1.06
Distinct roles of the two tumor necrosis factor (TNF) receptors in modulating TNF and lymphotoxin alpha effects. J Biol Chem (1996) 1.06
Porphyrin-sensitized photoinactivation of human cells in vitro. Am J Pathol (1982) 1.05
Selective inhibitors of cytosolic or secretory phospholipase A2 block TNF-induced activation of transcription factor nuclear factor-kappa B and expression of ICAM-1. J Immunol (1998) 1.05
Bacterial lipopolysaccharide induces expression of the stress response genes hop and H411. J Biol Chem (1999) 1.05
Beta 2 integrins are involved in cytokine responses to whole Gram-positive bacteria. J Immunol (2000) 1.04
Toll-like receptor 2 (P631H) mutant impairs membrane internalization and is a dominant negative allele. Scand J Immunol (2010) 1.04
Independent regulation of 55-kDa and 75-kDa tumor necrosis factor receptors during activation of human peripheral blood B lymphocytes. Eur J Immunol (1991) 1.04
Concomitant expression of hepatocyte growth factor/scatter factor and the receptor c-MET in human myeloma cell lines. J Biol Chem (1996) 1.01
Decreased serum lipocalin-2 levels in human immunodeficiency virus-infected patients: increase during highly active anti-retroviral therapy. Clin Exp Immunol (2008) 1.01
CD11/CD18 and CD14 share a common lipid A signaling pathway. J Immunol (1998) 1.00
Gene expression and secretion of cytokines and cytokine receptors from highly purified CD56+ natural killer cells stimulated with interleukin-2, interleukin-7 and interleukin-12. Eur J Immunol (1993) 1.00
Immunoregulatory effects of cytokines on natural killer cells. Scand J Immunol (1994) 0.98
Beryllium sensitivity among workers at a Norwegian aluminum smelter. Am J Ind Med (2010) 0.97
High level of fatigue in lymphoma patients treated with high dose therapy. J Pain Symptom Manage (2000) 0.96
Effects of IL-7 and IL-2 on highly enriched CD56+ natural killer cells. A comparative study. J Immunol (1991) 0.96
Characterization of binding and TNF-alpha-inducing ability of chitosans on monocytes: the involvement of CD14. Vaccine (1994) 0.96
Induction of tumor necrosis factor production from monocytes stimulated with mannuronic acid polymers and involvement of lipopolysaccharide-binding protein, CD14, and bactericidal/permeability-increasing factor. Infect Immun (1997) 0.96
Regulation of APO-2 ligand/trail expression in NK cells-involvement in NK cell-mediated cytotoxicity. Cytokine (1999) 0.95
Alginate polylysine microcapsules as immune barrier: permeability of cytokines and immunoglobulins over the capsule membrane. Cell Transplant (1997) 0.94
Cytokine levels in amniotic fluid and inflammatory changes in the placenta from normal deliveries at term. Eur J Obstet Gynecol Reprod Biol (1994) 0.92
An immunologic basis for the fibrotic reaction to implanted microcapsules. Transplant Proc (1991) 0.92
TNF production from peripheral blood mononuclear cells in diabetic patients after stimulation with alginate and lipopolysaccharide. Scand J Immunol (1996) 0.92
A flow cytometric and immunofluorescence microscopic study of tumor necrosis factor production and localization in human monocytes. Cell Immunol (1989) 0.92
Transplantation of alginate microcapsules: generation of antibodies against alginates and encapsulated porcine islet-like cell clusters. Transplantation (1999) 0.91
Human monocyte receptors involved in tumor necrosis factor responses to group B streptococcal products. Infect Immun (2000) 0.91
Molecular mechanisms in the compartmentalized inflammatory response presenting as meningococcal meningitis or septic shock. Microb Pathog (1992) 0.91
Regulation of Fas and Fas-ligand expression in NK cells by cytokines and the involvement of Fas-ligand in NK/LAK cell-mediated cytotoxicity. Cytokine (1997) 0.90
Polymorphonuclear granulocytes enhance lipopolysaccharide-induced soluble p75 tumor necrosis factor receptor release from mononuclear cells. Eur J Immunol (1995) 0.90
Disseminated Mycobacterium avium complex infection in AIDS: immunopathogenic significance of an activated tumor necrosis factor system and depressed serum levels of 1,25 dihydroxyvitamin D. J Infect Dis (1996) 0.89
Soluble TNF receptors in amniotic fluid and in urine from pregnant women. J Reprod Immunol (1992) 0.89
Influence of CD14, LBP and BPI in the monocyte response to LPS of different polysaccharide chain length. Scand J Immunol (1995) 0.89
Soluble CD14 from urine copurifies with a potent inducer of cytokines. Eur J Immunol (1994) 0.89
Current understanding of the pathogenesis of gram-negative shock. Infect Dis Clin North Am (1991) 0.88
IFN-gamma-induced production of monocyte cytotoxic factor. Cell Immunol (1985) 0.88
The cytokine stimulating activity of (1-->3)-beta-D-glucans is dependent on the triple helix conformation. Carbohydr Res (2000) 0.88
Differential effect of inhibiting MD-2 and CD14 on LPS- versus whole E. coli bacteria-induced cytokine responses in human blood. Adv Exp Med Biol (2012) 0.88
A rapid and sensitive immunoassay for tumor necrosis factor using magnetic monodisperse polymer particles. J Immunol Methods (1990) 0.87
The role of monocyte cytotoxic factor in monocyte-mediated lysis of tumour cells. Immunology (1986) 0.86
Involvement of the tumor necrosis factor receptor p75 in mediating cytotoxicity and gene regulating activities. Eur J Immunol (1994) 0.86
Elevated hepatocyte growth factor in sera from patients with insulin-dependent diabetes mellitus. Acta Diabetol (1998) 0.86
Stimulation of toll-like receptor 2 in mononuclear cells from HIV-infected patients induces chemokine responses: possible pathogenic consequences. Clin Exp Immunol (2004) 0.85
Monocytic cell activation by Nonendotoxic glycoprotein from Prevotella intermedia ATCC 25611 is mediated by toll-like receptor 2. Infect Immun (2001) 0.85
Expression of Toll-like receptor-3 is enhanced in active inflammatory bowel disease and mediates the excessive release of lipocalin 2. Clin Exp Immunol (2013) 0.85
Effects of intravenous immunoglobulin in vivo on abnormally increased tumor necrosis factor-alpha activity in human immunodeficiency virus type 1 infection. J Infect Dis (1997) 0.85
Involvement of CD14 and beta2-integrins in activating cells with soluble and particulate lipopolysaccharides and mannuronic acid polymers. Infect Immun (2000) 0.85
Increased levels of soluble tumor necrosis factor-alpha receptors in serum from pregnant women and in serum and urine samples from newborns. Pediatr Res (1993) 0.84
p55 and p75 tumor necrosis factor receptors in patients with chronic lymphocytic leukemia. Blood (1992) 0.83
Effect of antisera against recombinant tumor necrosis factor and the monocyte-derived cytotoxin(s) on monocyte-mediated killing of various tumor cells. Cell Immunol (1987) 0.83
Synergistic effects of interleukin 4 and interleukin 12 on NK cell proliferation. Cytokine (1993) 0.83
Tumor necrosis factor induces lipopolysaccharide tolerance in a human adenocarcinoma cell line mainly through the TNF p55 receptor. J Biol Chem (1995) 0.83
Immunomagnetic isolation of NK and LAK cells. J Immunol Methods (1991) 0.83
Soluble tumor necrosis factor receptor in serum and urine throughout normal pregnancy and at delivery. Am J Reprod Immunol (1995) 0.83
The role of interleukin-2 in regulating the sensitivity of natural killer cells for Fas-mediated apoptosis. Cancer Immunol Immunother (1999) 0.82
Compartmentalization of TNF and IL-6 in meningitis and septic shock. Mediators Inflamm (1993) 0.82
Apoptosis, proliferation and NF-kappaB activation induced by agonistic Fas antibodies in the human myeloma cell line OH-2: amplification of Fas-mediated apoptosis by tumor necrosis factor. Eur J Haematol (1999) 0.82